Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-label Randomized Study of MORAb-202 in Metastatic NSCLC Adenocarcinoma
2023-504112-15-00Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of farletuzumab ecteribulin in Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by Bristol Myers Squibb. Primary endpoint: Incidence and severity of adverse events and related safety outcomes. Started Apr 2024; status: completed.
02
Drugs
farletuzumab ecteribulin
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on 2023-504112-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504112-15-00.